New Research Finds Neurological Damage in Patients Hospitalized with COVID-19; Brain Scientific (BRSF) Appears Poised to Offer Technology That Can Help Understand How COVID-19 Affects Brain
As the world learns more about the novel SARS-CoV-2 virus, the evidence about neurological symptoms developed by patients who suffered from COVID-19 is mounting, and the market for Brain Scientific’s (OTCQB: BRSF) innovative products appears to expand. A recent article published in Medical News Today discusses findings of the observational study examining neurological issues in patients hospitalized with COVID-19. The research which appeared in the journal JAMA Network Open unveils that the most prevalent neurological symptom observed in the clinical setting was acute encephalopathy also finding a relationship between neurological issues and a higher risk of dying in the hospital in patients infected with the SARS-CoV-2 virus (https://nnw.fm/JwXkA).
Although COVID-19 is considered a respiratory disease that mainly affects patients’ pulmonary systems, research is increasingly documenting that the disease can affect many other organs and systems, including the brain. Since the start of the pandemic, it has been observed in a clinical setting that some patients with COVID-19 have also developed neurological symptoms. However, more than a year into the pandemic, medical professionals and scientists alike still do not fully understand the prevalence of neurological problems or their relationship with mortality risk.
To help fill this literature gap, Dr. Sherry Chou and her research team from the University of Pittsburgh School of Medicine performed an interim analysis of patient data collected from two large global consortia involving 3,744 patients across three cohorts. The study’s goal was to examine the incidence, type and outcomes of neurological manifestations among patients hospitalized with COVID-19.
What data revealed was astonishing. The first cohort involving 3,055 patients hospitalized with COVID-19, both with and without neurological symptoms, unveiled that the most prevalent clinically reported neurological sign was acute encephalopathy, found in 50% of patients, while the most frequent self-reported symptom was headache (38%), and the loss of taste or smell (28%). The second and third cohorts involving patients with confirmed neurological issues and those who had received a neurological consultation also show encephalopathy as the most common neurological issue (53% and 24%, respectively). Again, it was followed by headaches and the loss of taste and smell as the most common self-reporting neurological symptoms.
Research also reveals that if a patient has neurological issues resulting from COVID-19, it increases their risk of dying while in hospital by five times. Authors suggest that a formal neurological consultation may be needed in cases where doctors suspect neurological symptoms in individuals testing positive for COVID-19.
Although an association between neurological issues in COVID-19 patients and an increased risk of in-hospital mortality has been established, more research is needed to identify if these neurological symptoms are causing the increase in mortality. Notwithstanding some practical limitations of the study, it lays the groundwork for future research involving standardized protocols, which may be able to track patients with neurological issues after they leave the hospital.
As we learn more about the novel SARS-CoV-2 virus, it is becoming increasingly clear that neurological diagnostics will be at the center of the future post-COVID-19 health care of patients who suffered from the infection. Dr. Chou, the lead author of the study, emphasizes that even if we eradicate the pandemic, there are already millions of survivors who need neurological help, and there is still plenty of work in years to come.
As a commercial-stage health care company focused on developing innovative medical devices and software disrupting the brain diagnostics market, Brain Scientific is poised to be at the center stage of neurological diagnostics space offering solutions for this growing public health problem with its two commercialized and FDA-cleared devices, NeuroCap(TM) and NeuroEEG(TM). Committed to a vision to allow medical professionals to conduct brain activity studies and collect diagnostic information more quickly, Brain Scientific appears well-positioned to offer solutions for the growing market need in the post-pandemic world.
For more information, visit the company’s website at www.BrainScientific.com/Invest-Now.
NOTE TO INVESTORS: The latest news and updates relating to BRSF are available in the company’s newsroom at https://nnw.fm/BRSF
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
As the world learns more about the novel SARS-CoV-2 virus, the evidence about neurological symptoms developed by patients who suffered from COVID-19 is mounting, and the market for Brain Scientific’s (OTCQB: BRSF) innovative products appears to expand. A recent article published in Medical News Today discusses findings of the observational study examining neurological issues in patients hospitalized with COVID-19. The research which appeared in the journal JAMA Network Open unveils that the most prevalent neurological symptom observed in the clinical setting was acute encephalopathy also finding a relationship between neurological issues and a higher risk of dying in the hospital in patients infected with the SARS-CoV-2 virus (https://nnw.fm/JwXkA).
Although COVID-19 is considered a respiratory disease that mainly affects patients’ pulmonary systems, research is increasingly documenting that the disease can affect many other organs and systems, including the brain. Since the start of the pandemic, it has been observed in a clinical setting that some patients with COVID-19 have also developed neurological symptoms. However, more than a year into the pandemic, medical professionals and scientists alike still do not fully understand the prevalence of neurological problems or their relationship with mortality risk.
To help fill this literature gap, Dr. Sherry Chou and her research team from the University of Pittsburgh School of Medicine performed an interim analysis of patient data collected from two large global consortia involving 3,744 patients across three cohorts. The study’s goal was to examine the incidence, type and outcomes of neurological manifestations among patients hospitalized with COVID-19.
What data revealed was astonishing. The first cohort involving 3,055 patients hospitalized with COVID-19, both with and without neurological symptoms, unveiled that the most prevalent clinically reported neurological sign was acute encephalopathy, found in 50% of patients, while the most frequent self-reported symptom was headache (38%), and the loss of taste or smell (28%). The second and third cohorts involving patients with confirmed neurological issues and those who had received a neurological consultation also show encephalopathy as the most common neurological issue (53% and 24%, respectively). Again, it was followed by headaches and the loss of taste and smell as the most common self-reporting neurological symptoms.
Research also reveals that if a patient has neurological issues resulting from COVID-19, it increases their risk of dying while in hospital by five times. Authors suggest that a formal neurological consultation may be needed in cases where doctors suspect neurological symptoms in individuals testing positive for COVID-19.
Although an association between neurological issues in COVID-19 patients and an increased risk of in-hospital mortality has been established, more research is needed to identify if these neurological symptoms are causing the increase in mortality. Notwithstanding some practical limitations of the study, it lays the groundwork for future research involving standardized protocols, which may be able to track patients with neurological issues after they leave the hospital.
As we learn more about the novel SARS-CoV-2 virus, it is becoming increasingly clear that neurological diagnostics will be at the center of the future post-COVID-19 health care of patients who suffered from the infection. Dr. Chou, the lead author of the study, emphasizes that even if we eradicate the pandemic, there are already millions of survivors who need neurological help, and there is still plenty of work in years to come.
As a commercial-stage health care company focused on developing innovative medical devices and software disrupting the brain diagnostics market, Brain Scientific is poised to be at the center stage of neurological diagnostics space offering solutions for this growing public health problem with its two commercialized and FDA-cleared devices, NeuroCap(TM) and NeuroEEG(TM). Committed to a vision to allow medical professionals to conduct brain activity studies and collect diagnostic information more quickly, Brain Scientific appears well-positioned to offer solutions for the growing market need in the post-pandemic world.
For more information, visit the company’s website at www.BrainScientific.com/Invest-Now.
NOTE TO INVESTORS: The latest news and updates relating to BRSF are available in the company’s newsroom at https://nnw.fm/BRSF
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
